Oral Anti-Diabetes Drugs Market Prominent Growth Rate 2019 | Top Key Players, Demand Status Analysis, Share, Industry Size with Forecast Till 2024

Oral

TheOral Anti-Diabetes Drugs Marketresearch report 2019-2024 focuses on provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data. Oral Anti-Diabetes Drugs Market report also provides the current industry outlook with respect to key players, types, applications, countries and regions. The major drivers, restraints, opportunities and threats for key players is also included. It also provides granular analysis of market share, segmentation, revenue forecasts and regional analysis till 2024.

Market Overview:

  • The global oral anti-diabetes drug market is estimated to be USD 39.2 billion in 2019, and it is growing because of the rise in the Type 2 diabetes population.
  • Approximately 10% of diabetes cases worldwide contribute to Type 1 diabetes, and 90% of diabetes cases contribute to Type 2 diabetes.
  • The number of people who have diabetes is likely to reach 592 million by 2035. In 2013, the economic costs of diabetes across the world were estimated to be USD 548 billion.
  • Thus, the rise in prevalence of diabetes worldwide is likely to create a vast demand for diabetes drugs.

    Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/14244768

    Scope of the Report:

  • The global oral anti-diabetes drug market is segmented by drugs (biguanides, alpha-glucosidase inhibitors, dopamine-D2 receptor agonists, SGLT-2 inhibitors, DPP-4 inhibitors, sulfonylureas, and meglitinides) and geography.
  • A holistic study of the market has been carried out by incorporating various factors, extending from country-specific demographic conditions and business cycles to market-specific macroeconomic influences that are needed to analyze future trends. The research uncovers many paradigm shifts in the market studied, in terms of brand-level market dynamics.

    List of Key Manufacturers Covered in Oral Anti-Diabetes Drugs Market:

  • Takeda
  • Pfizer
  • Eli Lilly
  • Janssen Pharmaceuticals
  • Astellas
  • Boehringer Ingelheim
  • Merck And Co.
  • AstraZeneca
  • Bristol Myers Squibb
  • Novartis
  • Sanofi

    Oral Anti-Diabetes Drugs Market Report Covers the Following: –

    • The report covers forecast and analysis for the market on a global and regional level.
    • The report includes the drivers and the restraints that affect the growth of the market.
    • The report discusses detailed information about the market opportunities.
    • The market is segmented on the basis of product and end-user industry
    • The key target audience for the market has been determined in the report.
    • The revenue generated by the prominent industry players has been analyzed in the report.

    For More Information or Query or Customization Before Buying, Visit at – https://www.industryresearch.co/enquiry/pre-order-enquiry/14244768

    Oral Anti-Diabetes Drugs Market Report Highlights:

    • Comprehensive pricing analysis on the basis of product, application, and regional segments
    • The detailed assessment of the vendor landscape and leading companies to help understand the level of competition in the Oral Anti-Diabetes Drugs market
    • Deep insights about regulatory and investment scenarios of the Oral Anti-Diabetes Drugs market
    • Analysis of market effect factors and their impact on the forecast and outlook of the Oral Anti-Diabetes Drugs market
    • A roadmap of growth opportunities available in the Oral Anti-Diabetes Drugs market with the identification of key factors
    • The exhaustive analysis of various trends of the Oral Anti-Diabetes Drugs market to help identify market developments

    Key Market Trends: – DPP-4 Inhibitors Segment Has the Largest Market Share

    The DPP-4 inhibitors segment of the global oral anti-diabetes drug market was valued at USD 10,538.6 million in 2018, and it is expected to record a CAGR of 3.82% during the forecast period (2019-2024).
    DPP-4 inhibitor drugs are gaining momentum in the market because the products do not seem to have any effect on primary adverse cardiovascular outcomes and risk for heart failure.
    Besides, they can be used both as a combination therapy with insulin, sulphonylureas, and dipeptidyl peptidase-4 drugs, and as a monotherapy, thus, making it a widely used class of drugs.
    During the forecast period, the DPP-4 inhibitors segment is expected to witness constant growth rate, due to the introduction of new drugs that have improved efficacy, like glucagon-like peptide (GLP-1) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors. The segment is still expected to maintain the largest market share among all oral anti-diabetes drugs market segments.

    Asia Pacific leading the Oral Anti-diabetes Drugs Market

    Currently, North America holds the major share in the oral anti-diabetes drugs market. However, Asia-Pacific is expected to experience the highest growth rate during the forecast period.
    This is due to the high prevalence of diabetes in this region, which caused consequent adverse health and economic consequences.
    Moreover, an increase in the launch of new drugs with improved efficacy and high reimbursement for medicines is expected to have a positive impact on the oral anti-diabetes drugs market.
    India, China, and Japan lead the market, due to the growing diabetes population in the Asia-Pacific region.

    Purchase this Report (Price 5000 USD for single user license) – https://www.industryresearch.co/purchase/14244768

    Detailed TOC of Oral Anti-Diabetes Drugs Market Report 2019-2024:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Drivers
    4.3 Restraints
    4.4 Porter’s Five Forces Analysis
    4.4.1 Bargaining Power of Suppliers
    4.4.2 Bargaining Power of Consumers
    4.4.3 Threat of New Entrants
    4.4.4 Threat of Substitute Products and Services
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 By Drug
    5.1.1 Biguanides (Value and Volume 2012-2024)
    5.1.1.1 Metformins
    5.1.2 Alpha-glucosidase inhibitors (Value and Volume 2012-2024)
    5.1.2.1 Alpha-glucosidase Inhibitors
    5.1.3 Dopamine -D2 Receptor Agonist (Value and Volume 2012-2024)
    5.1.3.1 Bromocriptin (Cycloset)
    5.1.4 Sodium – glucose Cotransport -2 (SGLT-2) inhibitor (Value and Volume 2012-2024)
    5.1.4.1 Invokana (Canagliflozin)
    5.1.4.2 Jardiance (Empagliflozin)
    5.1.4.3 Farxiga/Forxiga (Dapagliflozin)
    5.1.4.4 Suglat (Ipragliflozin)
    5.1.5 Dipeptidyl Peptidase – 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)
    5.1.5.1 Januvia (Sitagliptin)
    5.1.5.2 Onglyza (Saxagliptin)
    5.1.5.3 Tradjenta (Linagliptin)
    5.1.5.4 Vipidia/Nesina (Alogliptin)
    5.1.5.5 Galvus (Vildagliptin)
    5.1.6 Sulfonylureas (Value and Volume 2012-2024)
    5.1.6.1 Sulfonylureas
    5.1.7 Meglitinides (Value and Volume 2012-2024)
    5.1.7.1 Meglitinides
    5.2 Geography
    5.2.1 North America
    5.2.1.1 United States (Value and Volume 2012-2024)
    5.2.1.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.1.2 Canada (Value and Volume 2012-2024)
    5.2.1.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.1.3 Rest of North America (Value and Volume 2012-2024)
    5.2.1.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.2 Europe
    5.2.2.1 France (Value and Volume 2012-2024)
    5.2.2.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.2.2 Germany (Value and Volume 2012-2024)
    5.2.2.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.2.3 Italy (Value and Volume 2012-2024)
    5.2.2.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.2.4 Spain (Value and Volume 2012-2024)
    5.2.2.4.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.2.5 United Kingdom (Value and Volume 2012-2024)
    5.2.2.5.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.2.6 Russia (Value and Volume 2012-2024)
    5.2.2.6.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.2.7 Rest of Europe (Value and Volume 2012-2024)
    5.2.2.7.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.3 Latin America
    5.2.3.1 Mexico (Value and Volume 2012-2024)
    5.2.3.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.3.2 Brazil (Value and Volume 2012-2024)
    5.2.3.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.3.3 Rest of Latin America (Value and Volume 2012-2024)
    5.2.3.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.4 Asia-Pacific
    5.2.4.1 Japan (Value and Volume 2012-2024)
    5.2.4.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.4.2 South Korea (Value and Volume 2012-2024)
    5.2.4.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.4.3 China (Value and Volume 2012-2024)
    5.2.4.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.4.4 India (Value and Volume 2012-2024)
    5.2.4.4.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.4.5 Australia (Value and Volume 2012-2024)
    5.2.4.5.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.4.6 Vietnam (Value and Volume 2012-2024)
    5.2.4.6.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.4.7 Malaysia (Value and Volume 2012-2024)
    5.2.4.7.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.4.8 Indonesia (Value and Volume 2012-2024)
    5.2.4.8.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.4.9 Philippines (Value and Volume 2012-2024)
    5.2.4.9.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.4.10 Thailand (Value and Volume 2012-2024)
    5.2.4.10.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.4.11 Rest of Asia-Pacific (Value and Volume 2012-2024)
    5.2.4.11.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.5 Middle East & Africa
    5.2.5.1 Saudi Arabia (Value and Volume 2012-2024)
    5.2.5.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.5.2 Iran (Value and Volume 2012-2024)
    5.2.5.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.5.3 Egypt (Value and Volume 2012-2024)
    5.2.5.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.5.4 Oman (Value and Volume 2012-2024)
    5.2.5.4.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.5.5 South Africa (Value and Volume 2012-2024)
    5.2.5.5.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.5.6 Rest of Middle & Africa (Value and Volume 2012-2024)
    5.2.5.6.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

    6 MARKET INDICATORS
    6.1 Type 1 Diabetes Population (2012-2024)
    6.2 Type 2 Diabetes Population (2012-2024)

    7 COMPETITIVE LANDSCAPE
    7.1 Company Profiles
    7.1.1 Takeda
    7.1.2 Pfizer
    7.1.3 Eli Lilly
    7.1.4 Janssen Pharmaceuticals
    7.1.5 Astellas
    7.1.6 Boehringer Ingelheim
    7.1.7 Merck And Co.
    7.1.8 AstraZeneca
    7.1.9 Bristol Myers Squibb
    7.1.10 Novartis
    7.1.11 Sanofi

    8 MARKET OPPORTUNITIES AND FUTURE TRENDS

     

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Autoimmune Diseases Treatment Market 2019 Analysis and In-Depth Research on Market Dynamics, Trends, Emerging Growth Factors and Forecasts To 2025

    Dicyandiamide (DCD) Market 2019 Size, Global Trends, Comprehensive Research Study, Development Status, Opportunities, Future Plans, Competitive Landscape and Growth by Forecast 2026

    Crossover Vehicles Market Size and Share Analysis 2019: Report Contains R&D, Designing, Manufacturing and Forecast Model 2025

    Sapphire Market 2019 | Global Industry Size, Share, Explosive Factors of Key Players, Future Trends and Industry Growth Rate Forecast to 2023

    Automotive Injector Nozzle Market Share, Size 2019 Growing Rapidly with Modern Trends, Development, Revenue, Demand and Forecast to 2024 | Says Industry Research Biz

  • Avatar

    sambit